Testing cooling treatment for severe lung failure in ICU patients
Part of Lungs & breathing clinical trials.
This trial tests whether therapeutic cooling (hypothermia) can improve outcomes in people with ARDS, a serious lung condition causing breathing failure. It may help by reducing harmful inflammation and lung injury, but eligibility is time-sensitive and requires ICU monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are in a participating ICU and on a breathing machine (a tube in the windpipe or a tracheostomy).
- You’ve been on the breathing machine for 7 days or less when screened.
- Chest imaging shows problems in both lungs, and it’s not fully explained by fluid around the lungs, collapsed lung, or certain fluid overload.
- Your oxygen levels are very low for ARDS (P/F ratio 200 or less) while PEEP is at least 8, or your team can estimate this from oxygen readings.
- You (or a legally authorized representative) can give consent for the study.
- The ARDS oxygen criteria (or the period when it qualifies) are met within 72 hours of enrollment/randomization.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a more careful ventilation approach for people with severe lung breathing failure (ARDS). It aims to improve outcomes by using a specific strategy for how the ventilator controls breathing.
This trial tests a new way of using a ventilator (TCAV) versus standard care for people with moderate-to-severe lung failure caused by community-acquired pneumonia. It aims to see if this approach can improve outcomes.
This pilot study tests NOA-001, a treatment given to people with ARDS (a serious lung condition) who are already on a breathing machine. It looks at whether the treatment can improve outcomes in ARDS caused by either non-COVID illnesses or COVID-19.
This trial observes the symptoms, treatments, and recovery of patients with acute respiratory distress syndrome (ARDS), a serious lung condition. It aims to learn more about how different types of breathing support affect outcomes.
This trial tests a new drug called LEAF-4L6715 to see if it helps people with severe acute respiratory distress syndrome (ARDS), a serious lung condition. If you are on a breathing machine and meet the criteria below, you may be able to join.
This study tests two types of breathing support—CPAP (a mask that pushes air into your lungs) and high-flow nasal oxygen (a special tube in your nose)—to see which works better for people with ARDS, a serious lung condition. It may help you breathe more easily without needing a breathing tube.
Hear when a new Respiratory Distress Syndrome, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.